ClinicalTrials.gg
Drug

Resatorvid clinical trials

Also written TAK-242.

studies test it
3
open now
0
in phase 3
2
first study started
2005

How each study uses resatorvid is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Resatorvid
2

Development codes

TAK-242
3

Studies by the year they started

3 studies that test it; most in 2005 (1)

Studies that test resatorvid, by start year
YearStudies
20051
20081
20201

By phase

A phase 1/2 study counts in both.

Phase 2
1
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 3 · Other 0

Takeda (2) · Akaza Bioscience Ltd (1)

Studies

Open first, then newest update. How each study uses resatorvid is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

As the comparator · 1 — what is tested is compared with resatorvid

Codes

What other systems call resatorvid · ClinicalTrials.gg INT004863

  • MeSH (NLM) C507035ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylateConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) H2MZ648C31RESATORVIDConfirmed FDA, NLM, Wikidata
  • Wikidata Q27088534resatorvidConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C87682ResatorvidOne source FDA
  • DrugBank DB05943One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.